Magic mushroom compound tested as opioid addiction aid

NCT ID NCT04161066

Recruiting now Symptom relief Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-phase study is testing whether adding two doses of psilocybin (the active ingredient in magic mushrooms) to standard buprenorphine/naloxone treatment is safe for adults with opioid use disorder. Ten participants will receive psilocybin along with counseling, while researchers monitor side effects, withdrawal symptoms, and changes in cravings. The goal is to see if psilocybin can safely support existing medication-assisted treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new way to help people with opioid use disorder stay in treatment and reduce cravings.
What could go wrong: This is a very small, early-phase safety study with only 10 participants, so results may not apply widely. Psilocybin can cause intense psychological effects and is not yet proven effective for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.